DK2818483T3 - Medicinsk sammensætning til behandling og/eller forebyggelse af cancer - Google Patents

Medicinsk sammensætning til behandling og/eller forebyggelse af cancer Download PDF

Info

Publication number
DK2818483T3
DK2818483T3 DK13752353.6T DK13752353T DK2818483T3 DK 2818483 T3 DK2818483 T3 DK 2818483T3 DK 13752353 T DK13752353 T DK 13752353T DK 2818483 T3 DK2818483 T3 DK 2818483T3
Authority
DK
Denmark
Prior art keywords
antibody
ser
seq
caprin
gin
Prior art date
Application number
DK13752353.6T
Other languages
English (en)
Inventor
Fumiyoshi Okano
Takanori Saito
Takayoshi Ido
Yoshitaka Minamida
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Application granted granted Critical
Publication of DK2818483T3 publication Critical patent/DK2818483T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Claims (16)

1. Antistof eller fragment deraf, som har immunologisk reaktivitet med et delvist CAPRIN-1-polypeptid bestående af aminosyresekvensen, der er vist i SEQ ID NO: 5.
2. Antistof eller fragment deraf ifølge krav 1, hvor antistoffet eller fragmentet deraf har cytotoksisk aktivitet mod en cancercelle, der udviser et CAPRIN-1 -protein.
3. Antistof eller fragment deraf ifølge krav 1 eller 2, hvor antistoffet er et mo-noklonalt antistof eller et polyklonalt antistof.
4. Antistof eller fragment deraf ifølge et af kravene 1 til 3, hvor antistoffet er et humant antistof, et humaniseret antistof, et kimærisk antistof, et enkeltkædet antistof eller et multispecifikt antistof.
5. Antistof eller fragment deraf ifølge et af kravene 1 til 4, hvor antistoffet eller fragmentet deraf omfatter: (i) en variabel region med tung kæde omfattende komplementaritetsbestemmende regioner bestående af aminosyresekvensen, der er vist i SEQ ID NO: 8, 9 og 10 (hhv. CDR1, CDR2 og CDR3) og en variabel region med let kæde omfattende komplementaritetsbestemmende regioner bestående af aminosyresekvensen, der er vist i SEQ ID NO: 11, 12 og 13 (hhv. CDR1, CDR2 og CDR3) og har immunologisk reaktivitet med CAPRIN-1-proteinet; eller (ii) en variabel region med tung kæde omfattende komplementaritetsbestemmende regioner bestående af aminosyresekvensen, der er vist i SEQ ID NO: 8, 9 og 14 (hhv. CDR1, CDR2 og CDR3) og en variabel region med let kæde omfattende komplementaritetsbestemmende regioner bestående af aminosyresekvensen, der er vist i SEQ ID NO: 11, 12 og 13 (hhv. CDR1, CDR2 og CDR3) og har immunologisk reaktivitet med CAPRIN-1-proteinet; eller (iii) en variabel region med tung kæde omfattende komplementaritetsbestemmende regioner med aminosyresekvenserne, der er vist i SEQ ID NO: 26, 27 og 28 (hhv. CDR1, CDR2 og CDR3) og en variabel region med let kæde omfattende komplementaritetsbestemmende regioner med aminosyre- sekvenserne, der er vist i SEQ ID NO: 30, 31 og 32 (hhv. CDR1, CDR2 og CDR3) og har immunologisk reaktivitet med CAPRIN-1-proteinet; eller (iv) en variabel region med tung kæde omfattende komplementaritetsbestemmende regioner med aminosyresekvenserne, der er vist i SEQ ID NO: 36, 37 og 38 (hhv. CDR1, CDR2 og CDR3) og en variabel region med let kæde omfattende komplementaritetsbestemmende regioner med aminosyresekvenserne, der er vist i SEQ ID NO: 40, 41 og 42 (hhv. CDR1, CDR2 og CDR3) og har immunologisk reaktivitet med CAPRIN-1-proteinet; eller (v) en variabel region med tung kæde omfattende komplementaritetsbestemmende regioner med aminosyresekvenserne, der er vist i SEQ ID NO: 46, 47 og 48 (hhv. CDR1, CDR2 og CDR3) og en variabel region med let kæde omfattende komplementaritetsbestemmende regioner med aminosyresekvenserne, der er vist i SEQ ID NO: 40, 41 og 42 (hhv. CDR1, CDR2 og CDR3) og har immunologisk reaktivitet med CAPRIN-1-proteinet.
6. Antistof eller fragment deraf ifølge krav 5 del (i), hvor antistoffet eller fragmentet deraf omfatter: (i) en variabel region med tung kæde bestående af aminosyresekvensen, der er vist i SEQ ID NO: 52 og en variabel region med let kæde bestående af aminosyresekvensen, der er vist i SEQ ID NO: 54 og har immunologisk reaktivitet med CAPRIN-1-proteinet; eller (ii) en variabel region med tung kæde bestående af aminosyresekvensen, der er vist i SEQ ID NO: 21 og en variabel region med let kæde bestående af aminosyresekvensen, der er vist i SEQ ID NO: 23 og har immunologisk reaktivitet med CAPRIN-1-proteinet; eller (iii) en variabel region med tung kæde bestående af aminosyresekvensen, der er vist i SEQ ID NO: 25 og en variabel region med let kæde bestående af aminosyresekvensen, der er vist i SEQ ID NO: 23 og har immunologisk reaktivitet med CAPRIN-1-proteinet.
7. Antistof eller fragment deraf ifølge krav 5 del (ii), hvor antistoffet eller fragmentet deraf omfatter en variabel region med tung kæde bestående af aminosyresekvensen, der er vist i SEQ ID NO: 16 og en variabel region med let kæde bestående af aminosyresekvensen, der er vist i SEQ ID NO: 18 og har immunologisk reaktivitet med CAPRIN-1-proteinet.
8. Antistof eller fragment deraf ifølge krav 5 del (iii), hvor antistoffet eller fragmentet deraf omfatter en variabel region med tung kæde bestående af aminosyresekvensen, der er vist i SEQ ID NO: 29 og en variabel region med let kæde bestående af aminosyresekvensen, der er vist i SEQ ID NO: 33 og har immunologisk reaktivitet med CAPRIN-1-proteinet.
9. Antistof eller fragment deraf ifølge krav 5 del (iv), hvor antistoffet eller fragmentet deraf omfatter en variabel region med tung kæde bestående af aminosyresekvensen, der er vist i SEQ ID NO: 39 og en variabel region med let kæde bestående af aminosyresekvensen, der er vist i SEQ ID NO: 43 og har immunologisk reaktivitet med CAPRIN-1-proteinet.
10. Antistof eller fragment deraf ifølge krav 5 del (v), hvor antistoffet eller fragmentet deraf omfatter en variabel region med tung kæde bestående af aminosyresekvensen, der er vist i SEQ ID NO: 49 og en variabel region med let kæde bestående af aminosyresekvensen, der er vist i SEQ ID NO: 43 og har immunologisk reaktivitet med CAPRIN-1-proteinet.
11. Antistof eller fragment deraf ifølge et af kravene 1 til 10, hvor antistoffet eller fragmentet deraf er konjugeret med et antitumormiddel.
12. Farmaceutisk sammensætning omfattende et antistof eller et fragment deraf ifølge et af kravene 1 til 11 som en aktiv bestanddel.
13. Kombinationslægemiddel omfattende en farmaceutisk sammensætning ifølge krav 12 og en farmaceutisk sammensætning, der omfatter et antitumormiddel.
14. Antistof eller fragment deraf ifølge et af kravene 1 til 11 eller farmaceutisk sammensætning ifølge krav 12 eller kombinationslægemiddel ifølge krav 13 til anvendelse i en fremgangsmåde til behandling og/eller forebyggelse af cancer.
15. Antistof, fragment, farmaceutisk sammensætning eller kombinationslægemiddel til anvendelse i en fremgangsmåde til behandling og/eller forebyggelse af cancer ifølge krav 14, hvor cancertypen er brystcancer, nyrecancer, pankreascancer, tyktarmscancer, lungecancer, hjernetumor, mavecancer, livmoderhalscancer, æggestokcancer, prostatacancer, urinblærecancer, spi-serørscancer, leukæmi, lymfom, fibrosarkom, mastocytom eller melanom.
16. DNA, der koder for et antistof eller fragmentet deraf ifølge et af kravene 1 til 10.
DK13752353.6T 2012-02-21 2013-02-21 Medicinsk sammensætning til behandling og/eller forebyggelse af cancer DK2818483T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012035238 2012-02-21
PCT/JP2013/054403 WO2013125654A1 (ja) 2012-02-21 2013-02-21 癌の治療及び／又は予防用医薬組成物

Publications (1)

Publication Number Publication Date
DK2818483T3 true DK2818483T3 (da) 2017-10-23

Family

ID=49005831

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13752353.6T DK2818483T3 (da) 2012-02-21 2013-02-21 Medicinsk sammensætning til behandling og/eller forebyggelse af cancer

Country Status (17)

Country Link
US (1) US9573993B2 (da)
EP (1) EP2818483B1 (da)
JP (1) JP6187256B2 (da)
KR (1) KR102005786B1 (da)
CN (1) CN104114582B (da)
AU (1) AU2013223161B2 (da)
BR (1) BR112014021102A2 (da)
CA (1) CA2864869C (da)
DK (1) DK2818483T3 (da)
ES (1) ES2643241T3 (da)
HU (1) HUE034736T2 (da)
IN (1) IN2014KN01715A (da)
MX (1) MX357505B (da)
PL (1) PL2818483T3 (da)
PT (1) PT2818483T (da)
RU (1) RU2631804C2 (da)
WO (1) WO2013125654A1 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009278386B2 (en) 2008-08-05 2015-05-21 Toray Industries, Inc. Pharmaceutical composition for treatment and prevention of cancers
RU2519089C2 (ru) 2008-08-05 2014-06-10 Торэй Индастриз, Инк. Способ обнаружения злокачественных опухолей
PL2532743T3 (pl) * 2010-02-04 2015-09-30 Toray Industries Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka
HUE033628T2 (en) 2011-08-04 2017-12-28 Toray Industries Method for detecting pancreatic cancer
US9409993B2 (en) * 2011-08-04 2016-08-09 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
IN2014KN01715A (da) 2012-02-21 2015-10-23 Toray Industries
DK2832366T3 (da) 2012-03-30 2018-01-22 Toray Industries Farmaceutisk sammensætning til behandling og/eller forebyggelse af galdeblærecancer
US9416193B2 (en) * 2012-03-30 2016-08-16 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of liver cancer
TR201902972T4 (tr) 2012-07-19 2019-03-21 Toray Industries Kanseri tespit etmek için yöntem.
US9753038B2 (en) 2012-07-19 2017-09-05 Toray Industries, Inc. Method for detecting cancer via measurement of caprin-1 expression level
MY181648A (en) 2012-08-24 2020-12-30 Univ California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
JP6447130B2 (ja) 2013-08-09 2019-01-09 東レ株式会社 癌の治療及び／又は予防用医薬組成物
JP6670297B2 (ja) * 2014-08-07 2020-03-18 メモリアル スローン ケタリング キャンサー センター 抗セラミド抗体
EP3402520A4 (en) * 2016-01-14 2019-01-02 BPS Bioscience, Inc. Anti-pd-1 antibodies and uses thereof
MX2018010485A (es) 2016-03-04 2019-01-10 Jn Biosciences Llc Anticuerpos para inmunoreceptor de celulas t con dominios de ig e itim (tigit).
CA3029003A1 (en) 2016-06-27 2018-01-04 The Regents Of The University Of California Cancer treatment combinations
WO2018009916A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
CA3041979A1 (en) 2016-10-28 2018-05-03 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
EP3777888A4 (en) 2018-03-30 2021-12-01 Toray Industries, Inc. PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
CA3142887A1 (en) 2019-06-13 2020-12-17 Bolt Biotherapeutics, Inc. Aminobenzazepine compounds, immunoconjugates, and uses thereof
BR112022006001A2 (pt) 2019-09-30 2022-07-12 Bolt Biotherapeutics Inc Imunoconjugado, composto de 8-amido-2-aminobenzazepina-ligante, composto de 5-amino-pirazoloazepina-ligante, composto de aminoquinolina-ligante, uso de um imunoconjugado e métodos para tratar câncer e para preparar um imunoconjugado
KR20220088901A (ko) 2019-10-25 2022-06-28 볼트 바이오테라퓨틱스 인코퍼레이티드 티에노아제핀 면역접합체, 및 이의 용도
US20230129035A1 (en) 2020-03-12 2023-04-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
JPWO2021182571A1 (da) 2020-03-12 2021-09-16
WO2021182570A1 (ja) 2020-03-12 2021-09-16 東レ株式会社 癌の治療及び／又は予防のための医薬品
EP4119159A4 (en) 2020-03-12 2024-03-27 Toray Industries MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
CA3175279A1 (en) 2020-03-12 2021-09-16 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
US20230293716A1 (en) 2020-05-08 2023-09-21 Bolt Biotherapeutics, Inc. Elastase-substrate, peptide linker immunoconjugates, and uses thereof
WO2021247591A1 (en) 2020-06-02 2021-12-09 Arcus Biosciences, Inc. Antibodies to tigit
AU2021326516A1 (en) 2020-08-13 2023-04-13 Bolt Biotherapeutics, Inc. Pyrazoloazepine immunoconjugates, and uses thereof
KR20240024803A (ko) 2021-06-23 2024-02-26 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
AU2022296193A1 (en) 2021-06-23 2024-01-18 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
WO2023008461A1 (ja) 2021-07-27 2023-02-02 東レ株式会社 癌の治療及び／又は予防のための医薬品
AU2022319362A1 (en) 2021-07-27 2024-02-29 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
KR20240041917A (ko) 2021-07-27 2024-04-01 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
WO2023033129A1 (ja) 2021-09-03 2023-03-09 東レ株式会社 癌の治療及び／又は予防用医薬組成物
CA3234604A1 (en) 2021-10-29 2023-05-04 Shelley Erin ACKERMAN Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof
WO2023177821A2 (en) * 2022-03-16 2023-09-21 Myeloid Therapeutics, Inc. Binding domains and methods of use thereof

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0770628B9 (en) 1994-07-13 2007-02-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
ES2364266T3 (es) 1998-04-03 2011-08-30 Chugai Seiyaku Kabushiki Kaisha Anticuerpo humanizado hacia el factor tisular humano (tf) y procedimiento para construir el anticuerpo humanizado.
US20030118599A1 (en) 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
RU2234942C2 (ru) 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
KR20070112860A (ko) 1998-07-14 2007-11-27 코릭사 코포레이션 전립선 종양 단백질의 분리된 면역원성 부위 및 이를사용하여 전립선암을 진단하는 방법
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
WO2000052204A2 (en) 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
WO2000060077A2 (en) 1999-04-02 2000-10-12 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP1224285A4 (en) 1999-10-29 2004-12-08 Human Genome Sciences Inc 27 HUMAN SECRETED PROTEINS
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
PL366626A1 (en) 2000-03-29 2005-02-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
ATE378403T1 (de) 2000-11-30 2007-11-15 Medarex Inc Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
RU2306952C2 (ru) 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
AU2002311787A1 (en) 2001-03-28 2002-10-15 Zycos Inc. Translational profiling
WO2002083070A2 (en) 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
AU2002311909A1 (en) 2001-05-11 2002-11-25 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CA2508763C (en) 2001-05-11 2012-01-24 Kirin Beer Kabushiki Kaisha Human antibody producing mouse and method for producing human antibody using the same
US20030190640A1 (en) 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
RU2319709C2 (ru) 2001-07-17 2008-03-20 Рисерч Дивелопмент Фаундейшн Терапевтические агенты, содержащие проапоптозные белки
JP2004535202A (ja) 2001-07-17 2004-11-25 リサーチ　ディベロップメント　ファンデーション アポトーシス促進性蛋白質を含む治療剤
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
WO2003072035A2 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20050003390A1 (en) 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
EP2314676A1 (en) 2002-11-26 2011-04-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004076682A2 (en) 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
AU2004235382A1 (en) 2003-04-29 2004-11-11 Wyeth Methods for diagnosing AML and MDS differential gene expression
JP2007516693A (ja) 2003-06-09 2007-06-28 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 癌の治療および診断のための組成物および方法
WO2005007830A2 (en) 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050032113A1 (en) 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
CA2553826A1 (en) 2004-01-26 2005-12-08 Debiovision Inc. Neoplasm-specific polypeptides and their uses
JP4734319B2 (ja) 2004-03-19 2011-07-27 イムクローン・リミテッド・ライアビリティ・カンパニー ヒト抗上皮成長因子受容体抗体
RU2429245C2 (ru) 2004-03-30 2011-09-20 Глаксо Груп Лимитед Иммуноглобулины
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
WO2006002378A2 (en) 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
US7449184B2 (en) 2005-01-21 2008-11-11 Genentech, Inc. Fixed dosing of HER antibodies
US7858324B2 (en) 2005-02-18 2010-12-28 Children's Medical Center Corporation Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
KR101310000B1 (ko) 2005-03-11 2013-09-25 싸이퍼젠 바이오시스템즈, 인코포레이티드 난소암 및 자궁내막암에 대한 바이오마커 : 헵시딘
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
EP1968622B1 (en) 2006-01-05 2014-08-27 The Ohio State University Research Foundation Microrna expression abnormalities in pancreatic endocrine and acinar tumors
CA2642342A1 (en) 2006-02-14 2007-08-23 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US20100015724A1 (en) 2006-08-17 2010-01-21 Peter Hornbeck Lysine acetylation sites
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7615349B2 (en) 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008059252A2 (en) 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
CN101836116A (zh) 2007-10-25 2010-09-15 东丽株式会社 癌的检测方法
JP5663834B2 (ja) 2008-03-14 2015-02-04 東ソー株式会社 遺伝子組換え抗体の製造方法
EP3692988A3 (en) 2008-03-18 2020-10-14 Genentech, Inc. Combinations of an anti-her2 antibody-drug conjugate and 5-fu, anti-vegf antibody, carboplatin or abt-869 and methods of use
KR101669827B1 (ko) 2008-08-05 2016-10-27 도레이 카부시키가이샤 면역 유도제
AU2009278386B2 (en) * 2008-08-05 2015-05-21 Toray Industries, Inc. Pharmaceutical composition for treatment and prevention of cancers
RU2519089C2 (ru) 2008-08-05 2014-06-10 Торэй Индастриз, Инк. Способ обнаружения злокачественных опухолей
PT2467401T (pt) 2009-08-19 2017-04-26 Merck Patent Gmbh Anticorpos para a deteção de complexos de integrina em material ffpe
CA2773240C (en) 2009-09-22 2015-11-10 Volker Sandig Process for producing molecules containing specialized glycan structures
KR101758117B1 (ko) 2010-02-04 2017-07-14 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
CN102821788B (zh) 2010-02-04 2016-11-16 东丽株式会社 癌的治疗和/或预防用药物组合物
MX342291B (es) * 2010-02-04 2016-09-23 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
AU2011211682B2 (en) 2010-02-04 2015-08-13 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
PL2532743T3 (pl) 2010-02-04 2015-09-30 Toray Industries Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka
JP5923984B2 (ja) 2010-02-04 2016-05-25 東レ株式会社 癌の治療及び／又は予防のための医薬品
KR101271964B1 (ko) 2010-07-08 2013-06-07 강원대학교산학협력단 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법
KR101576174B1 (ko) 2010-07-26 2015-12-09 르 라보레또레 쎄르비에르 간암 요법을 위한 방법 및 조성물
JP4937389B2 (ja) 2010-08-11 2012-05-23 三協技研工業株式会社 固液分離方法及び固液分離装置
HUE033628T2 (en) 2011-08-04 2017-12-28 Toray Industries Method for detecting pancreatic cancer
CA2844034C (en) 2011-08-04 2019-07-16 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
US9409993B2 (en) 2011-08-04 2016-08-09 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
KR101979208B1 (ko) 2011-08-04 2019-05-16 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
WO2013018891A1 (ja) 2011-08-04 2013-02-07 東レ株式会社 癌の治療及び／又は予防用医薬組成物
CA2844030C (en) 2011-08-04 2019-09-03 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
PT2740793T (pt) 2011-08-04 2018-02-23 Toray Industries Composição de fármacos para o tratamento e/ou a prevenção de cancro
KR102005308B1 (ko) 2012-02-21 2019-07-30 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
JP6187258B2 (ja) 2012-02-21 2017-08-30 東レ株式会社 癌の治療及び／又は予防用医薬組成物
IN2014KN01715A (da) 2012-02-21 2015-10-23 Toray Industries
RU2632645C2 (ru) 2012-02-21 2017-10-06 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
US9416193B2 (en) 2012-03-30 2016-08-16 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of liver cancer
DK2832366T3 (da) 2012-03-30 2018-01-22 Toray Industries Farmaceutisk sammensætning til behandling og/eller forebyggelse af galdeblærecancer
US9192530B2 (en) 2013-07-29 2015-11-24 Nacco Materials Handling Group, Inc. Moveable seat

Also Published As

Publication number Publication date
BR112014021102A2 (pt) 2021-12-28
AU2013223161B2 (en) 2017-10-19
US20150050283A1 (en) 2015-02-19
CA2864869A1 (en) 2013-08-29
EP2818483A1 (en) 2014-12-31
PL2818483T3 (pl) 2018-01-31
CA2864869C (en) 2021-10-19
EP2818483B1 (en) 2017-08-02
RU2014138041A (ru) 2016-04-10
EP2818483A4 (en) 2015-09-02
RU2631804C2 (ru) 2017-09-26
KR20140130669A (ko) 2014-11-11
JP6187256B2 (ja) 2017-08-30
PT2818483T (pt) 2017-10-09
JPWO2013125654A1 (ja) 2015-07-30
MX357505B (es) 2018-07-12
US9573993B2 (en) 2017-02-21
CN104114582A (zh) 2014-10-22
WO2013125654A1 (ja) 2013-08-29
HUE034736T2 (en) 2018-02-28
MX2014009746A (es) 2014-11-14
CN104114582B (zh) 2018-12-21
ES2643241T3 (es) 2017-11-21
AU2013223161A1 (en) 2014-09-11
IN2014KN01715A (da) 2015-10-23
KR102005786B1 (ko) 2019-07-31

Similar Documents

Publication Publication Date Title
DK2818483T3 (da) Medicinsk sammensætning til behandling og/eller forebyggelse af cancer
DK2740794T3 (da) Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
DK2740798T3 (da) Lægemiddelsammensætning til cancerbehandling og/eller forebyggelse
AU2013223143B2 (en) Pharmaceutical composition for treatment and/or prevention of cancer
DK2740795T3 (da) Lægemiddelsammensætning til behandling og/eller forebyggelse af cancer
DK2740793T3 (da) Lægemiddelsammensætning til cancerbehandling og/eller -forebyggelse
CA2864999C (en) Pharmaceutical composition for treatment and/or prevention of cancer
DK2740796T3 (da) Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
AU2013223147B2 (en) Pharmaceutical composition for treatment and/or prevention of cancer